Dynavax Technologies (NASDAQ:DVAX), Inc. (NASDAQ: DVAX) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of novel vaccines and immuno-oncology therapies. The company’s proprietary technology platform harnesses toll-like receptor 9 (TLR9) agonist biology to stimulate and enhance the immune response against infectious diseases and cancer. Dynavax’s scientific focus centers on leveraging its adjuvant expertise to improve vaccine efficacy, duration of protection and patient outcomes.
Dynavax’s flagship product, HEPLISAV-B, is a two-dose hepatitis B vaccine that received U.S. Food and Drug Administration approval in 2017. HEPLISAV-B demonstrated a robust immune response in adult populations, including those with weaker immune systems, and has since gained market authorizations in Canada and the European Union. In addition to infectious disease vaccines, the company is advancing oncology candidates such as SD-101, a synthetic CpG oligonucleotide designed to activate immune cells within the tumor microenvironment when combined with checkpoint inhibitors.
Dynavax operates from its headquarters in Berkeley, California, with a commercial presence and collaborations extending across North America, Europe and select Asia-Pacific markets. The company maintains strategic partnerships to accelerate development and broaden access to its vaccine technologies. These alliances include co-promotion and distribution agreements aimed at bolstering global immunization efforts against hepatitis B and other pathogens.
Founded in 1994, Dynavax has evolved from an early-stage research organization into a commercial vaccine company. Under the leadership of Chief Executive Officer Thomas Hay, Dynavax continues to build its pipeline and manufacturing capabilities while prioritizing regulatory engagement and market expansion. The company’s management team comprises industry veterans with deep expertise in vaccine development, regulatory affairs and global commercialization.
